Dr. Mark S. Morginstin, DO
Hematology & Oncology (Hematology & Oncology Physician)
5501 Old York Road, Albert Einstein Medical Center
Philadelphia, PA 19141
- Medicare participating
At a glance
- Medical school
- Rowan University School of Osteopathic Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 409
Licensed in Connecticut since 2004, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Rowan University School of Osteopathic Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
PA license OS011961 -
Internal Medicine Physician
CT license 042818 (first issued 2004; inactive)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jefferson Einstein Philadelphia Hospital Philadelphia, PA
- Jefferson Einstein Montgomery Hospital East Norriton, PA
- Jefferson Lansdale Hospital Lansdale, PA
Medical groups
- Einstein Practice Plan Inc (794 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 409
- Services billed
- 961
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 538 | 284 |
| Established patient office or other outpatient visit, 40-54 minutes | 145 | 78 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 83 | 80 |
| New patient office or other outpatient visit, 60-74 minutes | 63 | 63 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 40 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Philadelphia, PA | 211 |
| Eliquis (apixaban) Other prescribers in Philadelphia, PA | 167 |
| Hydroxyurea Other prescribers in Philadelphia, PA | 90 |
| Warfarin Sodium Other prescribers in Philadelphia, PA | 81 |
| Letrozole Other prescribers in Philadelphia, PA | 67 |
| Revlimid (lenalidomide) | 56 |
| Exemestane | 49 |
| Acyclovir Other prescribers in Philadelphia, PA | 34 |
| Ibrance (palbociclib) | 28 |
| Ondansetron Hcl Other prescribers in Philadelphia, PA | 25 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 12 payments worth $441 in total to this clinician.
| Sobi, Inc | $171 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $108 |
| Daiichi Sankyo Inc. | $52.34 |
| Eisai Inc. | $33.57 |
| Novartis Pharmaceuticals Corporation | $31.33 |
| Bayer HealthCare Pharmaceuticals Inc. | $25.79 |
| Pfizer Inc. | $19.64 |
| Food and Beverage | $248 |
|---|---|
| Education | $193 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sobi, Inc May 23, 2025 | Education in-kind | $92.99 |
| Sobi, Inc May 23, 2025 | Education in-kind | $77.99 |
| Daiichi Sankyo Inc. Jun 5, 2025 | Education Enhertu · ONCOLOGY · in-kind | $22.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $555 in research payments for these studies, mostly to the institutions running them.
- Chemo trastuzumab vs chemo trastuzumab pertuzumab
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.